Grace Therapeutics, Inc. Deferred Federal Income Tax Expense (Benefit)
Grace Therapeutics, Inc. (GRCE) reported Deferred Federal Income Tax Expense (Benefit) of -$1.49 million for the 12-month period ending 2026-03-31, per its 10-K filed 2026-06-18.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredFederalIncomeTaxExpenseBenefit · last filed 2026-06-18
- Grace Therapeutics, Inc. deferred federal income tax expense (benefit) for fiscal 2026 was -$1.49M.
- Grace Therapeutics, Inc. deferred federal income tax expense (benefit) for fiscal 2025 was -$2.39M.
- Grace Therapeutics, Inc. deferred federal income tax expense (benefit) for fiscal 2024 was -$1.83M.
| Period end | Deferred Federal Income Tax Expense (Benefit) 12 month |
|---|---|
| 2026-03-31 | -$1.49M 10-K · filed 2026-06-18 |
| 2025-03-31 | -$2.39M 10-K · filed 2026-06-18 |
| 2024-03-31 | -$1.83M 10-K · filed 2025-06-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |